Physician profile
Annette Osher
NPI 1225090640
$1,830.02
in general payments reported to CMS, 2019-2025
12 companies · $45.67 in 2025
The $45.67 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $116 · 2021: $225 · 2022: $312 · 2023: $244 · 2024: $132 · 2025: $45.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $693.72 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $598.77 | 2019-2025 | |
| Medtronic, INC. | $165.16 | 2023 | Corevalve Evolut R |
| Merck Sharp & Dohme LLC | $98.96 | 2024-2025 | Lagevrio, Dificid |
| Abbott Laboratories | $68.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $63.03 | 2022-2024 | Camzyos, Eliquis |
| Heartflow, INC. | $39.44 | 2024 | |
| Medicomp INC | $30.00 | 2022 | |
| Allergan, INC. | $20.38 | 2019 | |
| Boston Scientific Corporation | $19.67 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.87 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.72 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annette Osher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.